ReviewGastro hep advances2025
Use of Noninvasive Tests to Assess Clinically Significant Portal Hypertension and Response to Beta-Blockers.
Review in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- State-of-the-art review: ß-blockade in critical illness.Intensive care medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic venous pressure gradient is the gold standard for determining the presence of clinically significant portal hypertension and response to nonselective beta-blocker therapy. Of late, noninvasive tests (NITs) using algorithms based on blood tests, measurement of liver and splenic stiffness and radiomics have been found to reliably reflect stages of liver fibrosis and presence of portal hypertension. There is limited, but emerging evidence that NITs could be useful in predicting response to treatment with beta-blockers. In this review, we discuss the present status of the NITs in monitoring response and predicting nonresponse to nonselective beta-blockers therapy in patients with cirrhosis and clinically significant portal hypertension. This update also focuses on the benefits of NITs as they could be used dynamically with ease over prolonged periods.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.